Shepherd James, Hunninghake Donald B, Barter Philip, McKenney James M, Hutchinson Howard G
Department of Pathological Biochemistry, Royal Infirmary, University of Glasgow, Scotland, United Kingdom.
Am J Cardiol. 2003 Mar 6;91(5A):11C-17C; discussion 17C-19C. doi: 10.1016/s0002-9149(03)00004-3.
Both the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III and the Second Joint Task Force of European Societies guidelines have established low-density lipoprotein (LDL) cholesterol goals for lipid-lowering treatment to reduce the risk of coronary artery disease. Data from 3 trials that compared rosuvastatin 10 mg (n = 389) with atorvastatin 10 mg (n = 393) and 2 trials that compared rosuvastatin 10 mg (n = 226) with pravastatin 20 mg (n = 252) and simvastatin 20 mg (n = 249) were pooled separately to compare the achievement of LDL cholesterol goals over 12 weeks of treatment in hypercholesterolemic patients. Noncomparative pooling of rosuvastatin 10 mg results from all 5 trials (n = 615) showed that 80% achieved NCEP ATP III goals and 81% achieved the European goal of <3.0 mmol/L. Compared with atorvastatin 10 mg, significantly more patients treated with rosuvastatin 10 mg achieved their ATP III (76% vs 53%) and European (82% vs 51%) goals (p <0.001). Also, in comparisons with simvastatin 20 mg and pravastatin 20 mg, 86% of patients treated with rosuvastatin 10 mg achieved ATP III goals, compared with 64% of simvastatin-treated patients and 49% of pravastatin-treated patients (p <0.001). The proportions of patients who achieved the European goal were 80%, 48%, and 16% for rosuvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg, respectively, in this comparison (all p <0.001). A total of 71% of patients treated with rosuvastatin 10 mg who had triglyceride levels > or =200 mg/dL met both their LDL cholesterol and their non-high-density lipoprotein cholesterol goals.
美国国家胆固醇教育计划（NCEP）成人治疗专家组（ATP）III和欧洲学会第二联合工作组指南均已制定了低密度脂蛋白（LDL）胆固醇目标，用于降脂治疗以降低冠状动脉疾病风险。分别汇总了3项将瑞舒伐他汀10 mg（n = 389）与阿托伐他汀10 mg（n = 393）进行比较的试验数据，以及2项将瑞舒伐他汀10 mg（n = 226）与普伐他汀20 mg（n = 252）和辛伐他汀20 mg（n = 249）进行比较的试验数据，以比较高胆固醇血症患者在12周治疗期间LDL胆固醇目标的达成情况。对所有5项试验（n = 615）中瑞舒伐他汀10 mg的结果进行非对比汇总显示，80%的患者达到了NCEP ATP III目标，81%的患者达到了欧洲<3.0 mmol/L的目标。与阿托伐他汀10 mg相比，接受瑞舒伐他汀10 mg治疗的患者中达到ATP III目标（76%对53%）和欧洲目标（82%对51%）的患者明显更多（p<0.001）。此外，在与辛伐他汀20 mg和普伐他汀20 mg的比较中，接受瑞舒伐他汀10 mg治疗的患者中有86%达到了ATP III目标，而辛伐他汀治疗的患者为64%，普伐他汀治疗的患者为49%（p<0.001）。在此比较中，达到欧洲目标的患者比例分别为：瑞舒伐他汀10 mg组80%，辛伐他汀20 mg组48%，普伐他汀20 mg组16%（均p<0.001）。甘油三酯水平≥200 mg/dL的接受瑞舒伐他汀10 mg治疗的患者中，共有71%的患者同时达到了LDL胆固醇和非高密度脂蛋白胆固醇目标。
